NVIVQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVIVQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. InVivo Therapeutics Holdings's Average Total Inventories for the quarter that ended in Sep. 2023 was $0.00 Mil. InVivo Therapeutics Holdings's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.
InVivo Therapeutics Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2023 stayed the same from Jun. 2023 (0.00) to Jun. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
The historical data trend for InVivo Therapeutics Holdings's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InVivo Therapeutics Holdings Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
InVivo Therapeutics Holdings Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, InVivo Therapeutics Holdings's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where InVivo Therapeutics Holdings's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
InVivo Therapeutics Holdings's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
Inventory-to-Revenue (A: Dec. 2022 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2021 ) | + | Total Inventories (A: Dec. 2022 )) | / | count ) | / | Revenue (A: Dec. 2022 ) |
= | ( (0 | + | 0) | / | 1 ) | / | 0 |
= | 0 | / | 0 | ||||
= | N/A |
InVivo Therapeutics Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2023 is calculated as
Inventory-to-Revenue (Q: Sep. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Jun. 2023 ) | + | Total Inventories (Q: Sep. 2023 )) | / | count ) | / | Revenue (Q: Sep. 2023 ) |
= | ( (0 | + | 0) | / | 1 ) | / | 0 |
= | 0 | / | 0 | ||||
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InVivo Therapeutics Holdings (OTCPK:NVIVQ) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
InVivo Therapeutics Holdings's Days Inventory for the three months ended in Sep. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2023 ) | / | Cost of Goods Sold (Q: Sep. 2023 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
InVivo Therapeutics Holdings's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2023 ) | / | Average Total Inventories (Q: Sep. 2023 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Brice Foose | 10 percent owner | 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367 |
Daniel R Marshak | director | C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073 |
Christina Morrison | director | ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107 |
Richard M. Toselli | director, officer: CEO and CMO | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Richard Christopher | officer: Chief Financial Officer | C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623 |
C Ann Merrifield | director | |
Bob Rosenthal | director | 20 NEWBURY ST, BOSTON MA 02116 |
Heather Hamel | officer: Chief Legal Officer and GC | ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139 |
Jeffrey Modestino | officer: See Remarks | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139 |
Christopher Mcnulty | officer: Chief Financial Officer | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Melanie Golarz | officer: Interim CFO | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Jeffrey S. Hatfield | director | 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Pamela J Stahl | officer: Chief Commercial Officer | ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Richard John Roberts | director | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Masuoka K. Lorianne | officer: Chief Medical Officer | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
From GuruFocus
By Business Wire Business Wire • 04-14-2022
By Business Wire Business Wire • 10-22-2020
By Business Wire Business Wire • 06-02-2022
By Business Wire Business Wire • 04-16-2020
By Business Wire Business Wire • 09-08-2021
By Business Wire Business Wire • 09-09-2021
By Business Wire Business Wire • 10-27-2020
By Business Wire Business Wire • 01-06-2022
By Business Wire Business Wire • 03-05-2021
By Business Wire Business Wire • 07-13-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.